New antibody drugs aim to prevent deadly clots in PAD patients after leg surgery

NCT ID NCT07318610

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 5 times

Summary

This phase 3 trial is testing two experimental drugs, REGN7508 and REGN9933, to prevent serious blood clots in people with peripheral artery disease who recently had leg surgery to improve blood flow. The study will enroll about 7,050 participants and compare the drugs to a placebo and the standard blood thinner rivaroxaban. The goal is to see if these antibodies can reduce the risk of life-threatening events like limb loss, heart attack, or stroke.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN7508 (cenvacibart) and REGN9933 (amrecibart), monoclonal antibodies targeting factor XI
What this could lead to: If successful, these drugs could offer a new way to prevent life-threatening blood clots in people with peripheral artery disease after leg surgery, potentially with fewer bleeding risks than current treatments.
What could go wrong: This is a large phase 3 trial, but the drugs are still experimental. They may not work better than existing options, and side effects or unexpected bleeding risks could emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral arterial disease thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL ARTERY DISEASE (PAD)

Contacts and locations

Locations

Accellacare of Piedmont, Piedmont Healthcare
RECRUITING

Mooresville, North Carolina, 28117, United States
Apex Research Foundation, LLC
RECRUITING

Jackson, Tennessee, 38301, United States
Applied Research Center of Arkansas
RECRUITING

Little Rock, Arkansas, 72205, United States
Axsendo Clinical Research, Integrated Medical Services
RECRUITING

Avondale, Arizona, 85392, United States
Cardiovascular Solutions
RECRUITING

Shreveport, Louisiana, 71103, United States
Epic Medical Research
RECRUITING

DeSoto, Texas, 75115, United States
Epic Medical Research-Plano
RECRUITING

Plano, Texas, 75093, United States
Lake Martin Medical and Vascular Center
RECRUITING

Alexander City, Alabama, 35010, United States
Nature Coast Clinical Research - Cardiology
RECRUITING

Crystal River, Florida, 34429, United States
PharmaTex Research
RECRUITING

Amarillo, Texas, 79106, United States
Profound Research, Powers Health Medical Group
RECRUITING

Munster, Indiana, 46321, United States
Vanderbilt Heart and Vascular Tullahoma, Cardiology and Vascular Associates
RECRUITING

Tullahoma, Tennessee, 37388, United States
Vital Heart and Vein
RECRUITING

Cypress, Texas, 77429, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.